The RA NarRAtive Weighted Survey Methodology
The RA NarRAtive Patient Survey
The RA NarRAtive patient survey was fielded by Harris Poll across 16 countries from September 2014 to April 2016, and was replied to by 1,805 adults ages 18+ who have been diagnosed with rheumatoid arthritis (RA) in the U.S., and were primarily managed by a rheumatologist in Argentina (n=142), Australia (n=119), Brazil (n=163), Canada (n=67), France (n=64), Germany (n=171), Hong Kong (n=107), Italy (n=96), Japan (n=138), South Korea (n=127), Spain (n=59), Taiwan (n=45), Turkey (n=77), UK (n=66), and U.S. (n =192).1
Results from the RA NarRAtive patient sample survey may not reflect the experiences of the broader RA population.
The RA NarRAtive Physician Survey
The RA NarRAtive physician survey was conducted online by Harris Poll on behalf of Pfizer between August 14-October 2, 2015 among 1,736 rheumatologists ages 18+ who have seen at least five (5) RA patients in the past month whose RA was moderate to severely active, in Argentina (n=130), Australia (n=60), Brazil (n=150), Canada (n=50), France (n=149), Germany (n=150), Hong Kong (n=30), Italy (n=100), Japan (n=139), South Korea (n=100), Spain (n=100), Taiwan (n=100)1, Turkey (n=50), UK (n=150), and U.S. (n=208).1
Physician results in the United States were weighted by region, years in practice, and physician gender. In all other countries, raw data were not weighted at the individual country level (sample sizes noted above), and therefore are only representative of the individuals who completed the survey. For the global, 16-country total, a post-weight was applied to adjust for the relative size of each country's adult population within the total adult population across all countries surveyed. The unweighted sample sizes above reflect the total number of HCPs who completed the survey in each country, while all reported percentages are calculated based on the weighted global total described here.
RA NarRAtive physician sample survey may not reflect the experiences of all rheumatologists. Raw data were not weighted at the individual country level (except in the United States), and are therefore only representative of the individuals who completed the survey.
Where permitted, some members of the Global RA NarRAtive Advisory Panel were paid honoraria for their participation. Pfizer provided travel and accommodation, as well as a compensation, to Advisory Panel members who represent patient advocacy organizations for time spent developing the survey and attending meetings to review the survey findings.
The above methodology reflects survey data published in BMC - Health and Quality of Life Outcomes (November 2018)